

The background features a collage of images: a stylized eye with a white iris and black outline, a blue and white grid pattern, and a blue and white abstract shape. The text is overlaid on a dark blue horizontal band.

MicroPort Scientific Corporation



2022 Annual Results

March 2023

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

FORWARD-LOOKING STATEMENTS

Some information contained in this presentation contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words

"anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China and other countries that MicroPort operates in.

CONFIDENTIALITY

This presentation is confidential and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, in whole or in part, for any purpose.



Contents

- 1 **Company Highlights**
- 2 **Business Review**
- 3 **Financial Review**
- 4 **Outlook**
- 5 **Appendix Financial Statements**

Pursuit of innovation for 25 years

Core Business

cardio solutions

s cover main clinical spec


in
25 years

Global
medical
company

Uncompromising in
quality and relentless
pursuit of excellence


Industry leading
commercialization
capabilities

Building a super-conglomerate of people centric enterprises of
EMERGING MEDICAL TECHNOLOGIES



International revenue YOY, intl. DES revenue **up 63%** YOY
EMEA , South America , India JV %
Balloon revenue

Global Strategic Triangle






Contents

- 1 Company Highlights
- 2 Business Review
- 3 Financial Review
- 4 Outlook
- 5 Appendix Financial Statements

Business highlights

Revenue Overview

USD: million



* due to enormous depreciation of RMB against US\$



#1 China
#2 Global
Market share




2022 revenue \$134.1mn, up 2% YOY, despite the incessant impact of the pandemic
Guaranteed DES volume doubled in the continued procurement of VBP (v.s. 2020); newly approved Firebird Pro+® win the bid; bid-winning price increased of the renewal contract
DES products covered **3,200+** hospitals; balloon products covered **~1,500** hospitals; Firehawk newly developed **~200** hospitals


2022 revenue \$25.4mn, up 60% YOY (EMEA **+143%**, South America **+59%**), market share ramp up in multiple nations & achieved dominant position (incl. Argentina, Brazil, Thailand, etc.)
Indian JV thanks to our **multi-brand strategy**, as well as strong local India commercial & manufacturing capabilities of Firehawk
Accumulatively launched 40 countries; DES/ balloon received 8/ 6 new approvals, respectively

Firehawk TARGET IV-NA trial for FDA assessment **completed last enrollment**; Firesorb® released FUTURE-II 3-year follow-up results, completed FUTURE-III 1-year follow-up
Beyond catheter submitted NMPA; shockwave balloon & scoring balloon completed first enrollment
Coronary rapamycin **DCB** completed all patient enrollment; **1st** Chinese-developed coronary rotational atherectomy catheter under clinical trails & entered **NMPA Green Path**

Product pipeline



Non-China business



Business highlights

2022 revenue \$202.4mn, up 10% YOY, despite components & staffing shortage

EMEA recorded rapid revenue growth of **33%**, driven by strong double-digit growth in direct subsidiary markets and distributor markets

Market leading growth in **Knees**, thanks to global recognition of Medial Pivot

Released **ProFemur® Cemented XM Stem & HIPTURN Hip Tensioner**

Hinge knee joint system completed testing for FDA (510k); **Procotyl® P Cup** under testing for FDA (510k) assessment



Cost savings

Cost saving through continuous focusing on expense management

Kept enhancement of **collaboration between China and the US**, on-going projects incl. plasma spray, Evolution® & Advance® semi-finish


Multiple steps transferring from vendors to **in-house** manufacturing

Collaboration with Medbot

Skywalker™ installed in **4** hospitals in the US

First surgeries utilizing Skywalker™ robotics system with the Evolution™ knee performed in North America (Nov-22)

China business



Joints

2022 revenue \$21.1mn, up 2.9% YOY; 2H22 **increased by 68%** as compared with 1H22, amid COVID impact in China

Revenue of China-made joints increased by **208% YOY**, contributes **~33.4%** of the total sales

Fast growth of distribution channel, **up ~30% YOY**; hospital penetration remains steady growth; rapid enhancement of brand awareness

Five NMPA approvals, incl. new generation of China-made medial-pivot knee system & VenusOne Eco Bio-acetabular system & 3D knee planning system

Strong recovery in 2023, smooth progressing of cost-saving projects




Spine & Trauma

2022 revenue \$4.4mn, down 21.0% YOY, decrease mainly caused by reduced orders due to VBP policy

Leveraging the winning of national & provincial VBP tenders, total hospital coverage reached **1,000+**

Four NMPA approvals, **five** products to be submitted for NMPA review

Takin spinal posterior fixation system & arbores balloon dilatation system **successfully commercialized** in Argentina



1 One of the **ONLY 5** multi-national players

2022 revenue \$191.1mn, up 3% YOY, sales in Japan affected by Covid surf
Substantial sales growth in the Middle East (up 293% YOY), Latin America (up 249% YOY), and Austrilia (up 35% YOY)
Soaring sales of Bluetooth® pacemakers (already approved in EU & Japan &


ICD & CRT-D (1.5T/3T MRI)	ICD lead (1.5T/3T MRI)	Bluetooth® ICDs & CRT-Ds	Left Bundle Branch lead	Bluetooth® CRT-P (MRI)	Leadless pacemaker

Products newly approved for marketing



Note: 1. change of NMPA certificate; 2. revenue growth rate adjusted to exclude foreign exchange impact, due to appreciation or depreciation of US\$ against functional currencies

China business






1 Top 1 Chinese player No. 1 market share for China-made products



BeFlex lead (MRI OOC)	Rega® pacemaker (MRI OOC)	Platinum ICD	pacemakers (MRI) Veg lead (MRI)	Platinum CRT-D	Space HP ICD	BonaFire Passive Pacing lead (MRI)	ICD lead CRT lead (MRI)

Business highlights




Talos® Thoracic Stent Graft System


✓ **NMPA approved**

Cratos® Branched Aortics Stent Graft System

Launched clinical trials

Aegis® II Abdominal





China

2022 revenue \$79.9mn, up 43% YOY, thanks to sales burst of new products

Newly penetrated **~500** hospitals, total coverage reached **~2,600**; actively developed primary market, **Eagle & Swallows** program covered **~600** hospitals in lower-tier cities and counties, kept enhancing penetration

Tubridge® achieved rapid growth, gained **Top 1** market share in China (**45%**); NUMEN® won tenders in provincial VBPs, volume doubled (market share **5%**)

Top 1 market share, Bridge® sales rump up (**+~400%**)

Sales increment contribute by commercialization of **Neurohawk®** & **X-Rebridge®**, coil embolization assisting stent entered NMPA Green Path





International business generated revenue of \$3.2mn (up 3,492% YOY)


NUMEN® entered **7** countries/ regions, completed multiple commercial **Brazil**

NUMEN® sales ramp up in Korea, thanks to inclusion in medical insurance catalogue in 2022; fast business-promotion in the US leverage on sales network and complementary product portfolio of Rapid Medical (associated company)

Established subsidiaries in the **US, UK, Netherland**, and

	Product	Pre-clinical	Clinical	Registration
Hemorrhagic Stroke	nically Detachable Coil		✓ NMPA approved	
	Comaneci® Embolization Assist Device*		CE marked & FDA cleared	FDA Breakthrough Device Designation 
	Rebridge® Intracranial Visualized Stent		Admitted in NMPA Green Path	
Cerebral Atherosclerotic Stenosis	Balloon Dilatation Catheter		✓ NMPA approved	
	Intracranial Drug-Coated Balloon Catheter System		Design development	
	Neurohawk® Stent Thrombectomy Device		✓ NMPA approved	
Acute Ischemic Stroke	Tigertriever® Revascularization Device*		CE marked & FDA cleared	Submitted for NMPA review
	Tigertriever® 13 Revascularization Device*		✓ FDA cleared	
	X-Access Catheter		✓ NMPA approved	
	W-track® Intracranial Aspiration Catheter		Clinical trial waived	Submitted for NMPA review
	Balloon Guide Catheter		Clinical trial waived	Submitted for NMPA review

Business highlights



China

Revenue up 25% YOY, implantations up ~31% YOY (2,562 procedures), outperforming China market by 14 ppt²

GPM up 6 ppts, benefited from continuous effective cost-cut measures

Newly developed 130+ hospitals, total coverage reached ~440

Ramp up patient discovery and referral mechanism and continue to incubate TAVI centers and physicians



Non-China

Rapid overseas revenue growth, up 626% YOY

Gaining market share in Argentina & Colombia

Covered ~40 hospitals overseas, conducted ~100 commercial implantations

Alwide® Plus approved in Colombia & Thailand

CE marking progress under MDR regulations




R&D progress

VitaFlow® st steerable retrievable delivery system completed animal study, approaching design freeze stage

Self-developed TMVR system launched FIM, became st clinical-phase dry-tissue TMVR system, 6-month follow-up confirmed safety & efficacy

Alwide® balloon catheter III NMPA registration in progress

Product pipeline



Business highlights



	Product	Pre-clinical	Clinical	Registration
Laparoscopic	Toumai® Laparoscopic Surgical Robot	✓ Obtained NMPA		
	Toumai® 2 nd Generation		Submitted for NMPA review	
	Toumai® Single-arm Laparoscopic Surgical Robot		Started enrollment of registrational trial	
Orthopedic	Skywalker™ Orthopedic Surgical Robot	✓ Obtained NMPA approval ✓ Obtained FDA & CE approval		
	Spine Surgical Robot		Design validation stage	
Natural Orifice	Trans-bronchial Surgical Robot		Kick off enrollment in near term	
Panvascular	R-ONE® Vascular Interventional Surgical Robot		Submitted for NMPA review Obtained CE in 2019	
	TAVR Surgical Robot		Design development stage	
Percutaneous	Transperineal Prostate Biopsy System		Submitted for NMPA review Obtained CE & FDA in 2017	
	Thoracic and Abdominal Puncture Robot		Design validation stage	

Product admitted in NMPA Green Path












Business overview

Provider of **complete and systematic life support solutions for acute critical cases**, product portfolio includes ECMO system, oxygenator, etc.
2022 revenue \$4.5mn, strongly affected by the pandemic
1st highly integrated China-developed membrane oxygenator, Vitasprings

Product overview

Flagship MOBYBOX ECMO System

1st fully integrated ECLS system to provide both blood flow and gas management in a single device
 Study confirms its safety and efficacy in treating ARDS
 Received 2022 German Design Award of Medical Device

	Product	Pre-clinical	Clinical	Registration
Emergency transport system	Hemovent ¹ MOBYBOX [®] ECMO 	✓ Obtained CE mark		
	Hemovent ¹ MOBYO [™] ECMO Oxygenator	✓ Obtained CE mark		
	Hemovent ¹ WATCHA blood oxygen saturation monitoring sensor	✓ Obtained CE mark		
ECMO	Centrifugal ECMO system			
	Double lumen cannula			
	Transseptal cannula			
CPB		✓ Obtained NMPA approval		
	Cannula series	✓ Obtained NMPA approval & CE mark		
	Femoral cannula series	✓ Submitted NMPA application		
Congenital heart diseases	Atrial septal defect occluder 	✓ Obtained NMPA approval		
	Patent ductus arteriosus occluder 	✓ Obtained NMPA approval		
	Ventricular septal defect occluder 	✓ Obtained NMPA approval		
	Occluder delivery system 	✓ Obtained NMPA approval		
	Patent foramen ovale occluder 			
Others	Patient monitoring system	Data processing platform	ICU management	Heart failure
				In-hospital transport system

	Product	Indication	Pre-clinical	Clinical	Registration
OCT	Insight-100 ArgusClarity	PCI	✓ Obtained NMPA approval		
	Insight-100 1350 NOPURGE (OCT catheter)	PCI	✓ Obtained NMPA approval		
	Insight-100h High Speed OCT	PCI	✓ Obtained NMPA approval		
	High Resolution OCT	PCI	Clinical trial waived		
	Peripheral/Intracranial OCT	Panvascular			
Multi-module interventional	Soul-Man DSA System	Interventional	✓ Obtained NMPA approval		
	Coronary Artery IVUS	PCI	✓ Submitted for type examination		
	Peripheral/Intracranial IVUS	Panvascular			
	IVUS-ICE	SHD			
	OCT+IVUS	PCI	✓ Prototype development stage		
MRI	OCT+IVUS+FFR	PCI			
	Imported MRI System	Prostate biopsy	✓ Obtained FDA approval		
	Chinese MRI System	Prostate biopsy			

Business highlights

Provide innovative total solutions in endoscope and disposal devices to **urological, gastrointestinal, gynecological & respiratory** diseases, **18 NMPA** certificates in total

Two single-use digital endoscope, flexible ureteroscope catheter & choledochoscope catheter approved by **NMPA**

Ruyi **NMPA** st hemostatic clip for large wound closure used in the GI tract

R&D progress

30+ in pipeline

1 Products obtained

Key product 1st in China, 2nd globally

Prostatic urethral lift system admitted in **NMPA Green Path** and completed FIM, began patient enrollment for registration clinical trial

Globalization

5 received overseas registration approvals

3 submitted registration application for CE mark

	Product	Indication	Pre-clinical	Clinical	Registration
Single-use endoscope	Single-use digital ureteroscope catheter	Urology	✓	Obtained NMPA approval	
	Single-use digital choledochoscope catheter	Gastroenterology	✓	Obtained NMPA approval	
	7 other candidates covering urological, gastrointestinal, gynecological and respiratory indications				
Reusable endoscope	3 candidates covering gastrointestinal and respiratory indications				
Passive consumables	Nephrostomy balloon dilation catheter		✓	Obtained NMPA approval	
	Single-use endoscopic retrieval basket (3 claws)		✓	Obtained NMPA approval	
	Ureteral access sheath		✓	Obtained NMPA approval	
	Single-use urinary track guidewire	Urology	✓	Obtained NMPA approval	
	Ureter balloon dilation catheter		✓	Obtained NMPA approval	
	Prostatic urethral lift system		✓	Launched registration trial	
	Hybrid zebra guidewire				
	Ultrathin basket				
	Ruyi	Gastroenterology	✓	Obtained NMPA approval	
	6 other candidates covering gastrointestinal and urological indications				
Energy-based	5 candidates covering general, gynecological and gastrointestinal indications				
Neuro modulation	3 candidates covering urological and respiratory indications				

 Product admitted in NMPA Green Path

Business highlights

- ◆ 2022 revenue increased by **37% YOY** with profitability
- ◆ **TOP 1** Chinese 3D catheter RF ablation player with **30,000+** 3D navigation cases performed
- ◆ Successful **IPO on SSE STAR** board (Aug 31, 2022)
- ◆ **26 NMPA** certificates & **5 NMPA green path** products
- ◆ EasyStars & TrueForce® obtained **NMPA**; IceMagic® cryoablation system & catheter submitted for **NMPA**
- ◆ Multiple products **won tenders** in Fujian provincial-league VBP (covered 27 provinces), especially for EasyStars

Globalization

- ◆ **One** of the few global players with all-around EP solutions
- ◆ Products entered **30** overseas countries
- ◆ **4 FDA** clearances obtained in 2022; **4 CE** markings
- ◆ Core product TrueForce® submitted for **CE**

Materials & intelligent manufacturing service¹

- ◆ **upstream raw material, CDMO and testing**
- ◆ Excellent supply chain & quality management capabilities, passing rate **over 95%**
- ◆ Scalable production with annual capacity **~30mm** components, serving **100+** customers
- ◆ Fast revenue growth with strong profitability, 2022 revenue **increased by 37% YOY**

Contract Sterilization¹

- ◆ 2022 revenue boost, **up 268% YOY**, mainly attribute to fast-growing external orders (contributes **62% of the total revenue**)
- ◆ Newly obtained CNAS(ISO17025:2017 in 2022)

Pharmaceuticals (API)

- ◆ 2022 revenue **up 330%**, remains consecutive strong growth
- ◆ Engaged in **characteristic microbial fermentation APIs** incl. rapamycin, cyclosporine, tacrolimus and mycophenolate mofetil, with sales scope already covering **US, Japan & EU**

MicroPort 微创

Sports medicine¹

- ◆ **Multiple** products newly approved, incl. **Galaxy Insight** 4K high-resolution arthroscope system, **Endosharp®** sterile disposable shaving tip series, **Javelot®** titanium wireline anchor system & PEEK wireline anchor system, etc.
- ◆ long-term implantable rotator cuff spacer system, Archimedes® completed patient enrollment of registration trial in China, submitted for CE approval, and entered **FDA** pre-submission stage

Rehabilitation

- ◆ TherMotion®, cryo-thermo compression device **commercialized** in China, gained market approval in the **US and Columbia**
- ◆ REBRAIN® lower limb rehabilitative training robot approved by the **NMPA**
- ◆ Suzhou rehabilitation clinic entered trial operation stage

Skin care¹

- ◆ **2022 revenue up 314% YOY**, thanks to rapid sales growth of micro-needle product series;
- ◆ Flagship products, anti-acne HA micro-patch/ deep infusion recovering microcrystalline eye patch recorded sales volume of **285K/ 80K**, respectively

Assisted reproductive technology (ART)¹

- ◆ Provide solutions of ART treatment, **2022 revenue up 724% YOY**
- ◆ Daylily® embryo transfer catheter received **FDA approval**; **3** products obtained **NMPA**, artificial insemination catheter approved in **Thailand**

Blood glucose, tumor chemotherapy delivery & pain management¹

- ◆ AutoEx® chemotherapy pump **successfully commercialized** in China
- ◆ Patient-controlled analgesia (PCA) pump & peripherally inserted central catheter (PICC) submitted for **NMPA**; CGM submitted for type examination



Contents

1 Company Highlights


2 Business Review

3 Financial Review

4 Outlook

Revenue

USD: million




Gross profit margin




Operating expenses

USD: million




Total net loss & net loss attributable to equity shareholders

USD: million



Sales & marketing expenses

USD: million




Sales & marketing expenses increased by 10.3%^{YOY}

- Increase in marketing activities and product promotion

Administrative expenses

USD: million




Administrative expenses decreased by 1.0%^{YOY}

- Due to the Group's effective cost control and scale of operations.

R&D expenses

USD: million



R&D expenses increased by 41.0%^{YOY}

- Due to increased investments in R&D projects



Contents

- 1 Company Highlights
- 2 Business Review
- 3 Financial Review
- 4 Outlook
- 5 Appendix Financial Statements

Innovative product pipeline fueling long-term growth

Cardio-vascular	Micro-catheter NMPA	Anchor Balloon NMPA	Firesorb® Bioresorbable Scaffolds NMPA&CE	Coronary Rotational Atherectomy System NMPA&CE	Scoring Balloon NMPA	Coronary Rapamycin DCB NMPA	Firehawk® FDA	Coronary Stent Graft System NMPA	Intravascular Lithotripsy Balloon NMPA&CE
Orthopedics	Classic Profemur® Cemented XM® Femoral Stem FDA		Zirconium Niobium Alloy Femoral Head NMPA	Hinged Knee Joint System FDA		Evolution Tibia Cones FDA	2D-to-3D Imaging Technology FDA	Wrist Joint Prosthesis System NMPA	
CRM	Bluetooth® ICD & CRT-D CE		Pacemaker & BonaFire Passive Lead (MRI) NMPA	Space HP ICD/CRT-D NMPA		Invicta ICD Lead & " CRT Lead (MRI) NMPA	LBB pacing lead CE	Leadless Pacemaker NMPA&CE	
Endo-vascular	Vflower® Iliac Venous Stent System NMPA		Fishhawk Thrombectomy Catheter NMPA	Vena Cava Filter NMPA		Cratos Branched Aortic Stent Graft System NMPA	Aegis® II Abdominal Aortic Stent Graft System NMPA	TIPS Stent Graft System NMPA	
Neuro-vascular	Tigertriever Revasculari- zation Device NMPA		X- Intracranial Distal Access Catheter NMPA	Comaneci® Embolization Assist Device NMPA		Rebridge® Intracranial Visualized Stent NMPA	diverting Stent NMPA	Balloon Protection Guiding Catheter NMPA	
Heart Valve	VitaFlow® III NMPA	VitaFlow Novo Generation NMPA	VitaFlow® Balloon Expandable NMPA	Mitral Replacement: Self-developed replacement product		Mitral Replacement: AltaValve "	Mitral Repair: Self-developed edge to edge repair product	Tricuspid Repair: Self-developed edge to edge repair product Trivid	
Surgical Robot	Toumai® 2 nd Gen Laparoscopic Surgical Robot NMPA		R-ONE® Panvascular Surgical Robot NMPA	" " Robotic Transperineal Prostate Biopsy System NMPA		Toumai® Single-arm Laparoscopic Surgical Robot	Trans- bronchial Surgical Robot NMPA	TAVR Surgical Robot NMPA	Spine Surgical Robot NMPA
Surgical Devices	Femoral Arterial & Venous Cannula NMPA		Arterial Micro-Embolic Filter (new type) NMPA	MOBYBOX System NMPA		Centrifugal ECMO system NMPA	Double lumen cannula NMPA	Transeptal cannula NMPA	
Electro- physiology¹	System V4 NMPA	" "	IceMagic® Cardiac Cryoablation System NMPA			Cryoablation Catheter NMPA	Renal RF Ablation System NMPA	Flashpoint® Renal Artery Ablation Catheter NMPA	



Contents

1 Company Highlights

2 Business Review

3 Financial Review

4 Outlook



USD'000	2022	2021	Var.
Revenue	840,831	778,639	8.0%
Cost of sales	(339,060)	(286,866)	18.2%
Gross profit	501,771	491,773	2.0%
Other net income	36,150	76,475	-52.7%
Research and development costs	(419,828)	(297,778)	41.0%
Distribution cost	(328,232)	(297,532)	10.3%
Administrative expenses	(247,532)	(250,010)	-1.0%
Other operating costs	(49,279)	(16,547)	197.8%
Loss from operations	(506,950)	(293,619)	72.7%
Finance cost	(78,401)	(47,883)	63.7%
Gain on deemed disposal of a subsidiary	7,107	8,218	-13.5%
Gain on deemed disposal of interest in equity-accounted investees	39,267	9,215	326.1%
Share of losses of equity-accounted investees	(42,541)	(13,255)	220.9%
Loss before taxation	(581,518)	(337,324)	72.4%
Income tax	(6,597)	(13,971)	-52.8%
Loss for the period	(588,115)	(351,295)	67.4%
Attributable to: Equity shareholders of the Company	(436,515)	(276,484)	57.9%

USD'000	31 Dec 2022	31 Dec 2021	Var.
Non-current assets			
Investment properties	6,579	7,407	-11%
Other property, plant and equipment	993,014	922,874	8%
Intangible assets	223,683	256,609	-13%
Goodwill	262,829	290,565	-10%
Equity-accounted investees	423,873	363,103	17%
Other financial assets	23,155	30,184	-23%
Deferred tax assets	27,637	20,368	36%
Other non-current assets	94,081	102,652	-8%
Total non-current assets	2,054,851	1,993,762	3%
Current assets			
Inventories	352,428	289,931	22%
Trade and other receivables	284,833	308,126	-8%
Pledged deposits and time deposits	60,765	32,890	85%
Cash and cash equivalents	1,203,007	1,754,414	-31%
Derivative financial assets	38,201	1,406	2617%
Total current assets	1,939,234	2,386,767	-19%
Current liabilities			
Trade and other payables	380,554	358,792	6%
Contract liabilities	22,598	23,590	-4%
Lease liabilities	51,944	50,505	3%
Interest-bearing borrowings	185,387	94,746	96%
Income tax payable	17,470	19,124	-9%
Derivative financial liabilities	4,172	-	N/A
Total current liabilities	662,125	546,757	21%
Net current assets	1,277,109	1,840,010	-31%

Interest-bearing borrowings	336,689	269,637	25%
Lease liabilities	124,373	168,437	-26%
Deferred income	38,123	35,098	9%
Convertible bonds	769,553	660,369	17%
Contract liabilities	24,839	26,243	-5%
Other payables	220,997	425,914	-48%
Deferred tax liabilities	24,718	27,692	-11%
Derivative financial liabilities	-	2,890	-100%
Total non-current liabilities	1,539,292	1,616,280	-5%
CAPITAL AND RESERVE			
Share capital	18	18	-
Reserves	1,135,012	1,490,732	-24%
Total equity attributable to equity shareholders of the Company	1,135,030	1,490,750	-24%
Non-controlling interests	657,638	726,742	-10%
Total equity	1,792,668	2,217,492	-19%

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

FORWARD-LOOKING STATEMENTS

Some information contained in this presentation contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words

"anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China and other countries that MicroPort operates in.

CONFIDENTIALITY

This presentation is confidential and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, in whole or in part, for any purpose.